Home>>Signaling Pathways>> Membrane Transporter/Ion Channel>> Sodium Channel>>Eleclazine hydrochloride (GS 6615 hydrochloride)

Eleclazine hydrochloride (GS 6615 hydrochloride) (Synonyms: GS 6615 hydrochloride)

Catalog No.GC30063

Eleclazine (GS 6615) hydrochloride is a selective cardiac late sodium current inhibitor and a weak inhibitor of potassium current with IC50 value of <1 μM and approximately 14.2 μM, respectively.

Products are for research use only. Not for human use. We do not sell to patients.

Eleclazine hydrochloride (GS 6615 hydrochloride) Chemical Structure

Cas No.: 1448754-43-5

Size Price Stock Qty
10mM (in 1mL DMSO)
$238.00
In stock
1mg
$103.00
In stock
5mg
$270.00
In stock
10mg
$405.00
In stock
25mg
$754.00
In stock
50mg
$1,215.00
In stock
100mg
$1,576.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Eleclazine hydrochloride is a novel late Na+ current inhibitor with IC50 value of 0.7 uM. target: Na+ current.IC50: 0.7 uM.In vitro: Eleclazine hydrochloride inhibits ATX-II enhanced late INa in ventricular myocytes, shorten the ATX-II induced prolongation of APD, MAPD, QT interval, and decreased spatiotemporal dispersion of repolarization and ventricular arrhythmias. Inhibition by GS-6615 of ATX-II enhanced late INa is strongly correlated with shortening of myocyte APD and isolated heart MAPD[1]. Selective inhibition of cardiac late INa with eleclazine hydrochloride confers dual protection against vulnerability to ischemia-induced AF and reduces atrial and ventricular repolarization abnormalities before and during adrenergic stimulation without negative inotropic effects. [2]

[1]. Rajamani S et al. The novel late Na+ current inhibitor, GS-6615 (eleclazine) and its anti-arrhythmic effects in rabbit isolated heart preparations. Br J Pharmacol. 2016 Jul 23. [2]. Justo F et al. Inhibition of the cardiac late sodium current with eleclazine protects against ischemia-induced vulnerability to atrial fibrillation and reduces atrial and ventricular repolarization abnormalities in the absence and presence of concurrent a

Reviews

Review for Eleclazine hydrochloride (GS 6615 hydrochloride)

Average Rating: 5 ★★★★★ (Based on Reviews and 33 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Eleclazine hydrochloride (GS 6615 hydrochloride)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.